


Listing of Claims:

There are no amendments to the claims made herein.


1. (Original) A compound having the formula:



where Y_1 and Y_2 , which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group.

2. (Original) 2-methylene-19-nor-20(S)-25-methyl-1 α -hydroxycalciferol.
3. (Original) A pharmaceutical composition containing at least one compound as claimed in claim 1 together with a pharmaceutically acceptable excipient.
4. (Original) The pharmaceutical composition of claim 3 containing 2-methylene-19-nor-20(S)-25-methyl-1 α -hydroxycalciferol in an amount from about 0.01 μ g to about 100 μ g.
5. (Original) The pharmaceutical composition of claim 3 containing 2-methylene-19-nor-20(S)-25-methyl-1 α -hydroxycalciferol in an amount from about 0.1 μ g to about 50 μ g.

6. (Original) A method of treating metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of a compound having the formula:



where Y_1 and Y_2 , which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group.

7. (Original) The method of claim 6 where the disease is senile osteoporosis.
8. (Original) The method of claim 6 where the disease is postmenopausal osteoporosis.
9. (Original) The method of claim 6 where the disease is steroid-induced osteoporosis.
10. (Original) The method of claim 6 where the disease is low bone turnover osteoporosis.
11. (Original) The method of claim 6 where the disease is osteomalacia.
12. (Original) The method of claim 6 where the disease is renal osteodystrophy.
13. (Original) The method of claim 6 wherein the compound is administered orally.


14. (Original) The method of claim 6 wherein the compound is administered parenterally.

15. (Original) The method of claim 6 wherein the compound is administered transdermally.

16. (Original) The method of claim 6 wherein the compound is administered in a dosage of from 0.01 μg to 100 μg per day.

17. (Original) The method of claim 6 wherein the compound is 2-methylene-19-nor-20(S)-25-methyl-1 α -hydroxycalciferol.

18. (Original) A method of treating psoriasis comprising administering to a patient with said disease an effective amount of a compound having the formula:




where Y_1 and Y_2 , which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group.

19. (Original) The method of claim 18 wherein the compound is 2-methylene-19-nor-20(S)-25-methyl-1 α -hydroxycalciferol.

20. (Original) The method of claim 18 wherein said effective amount comprises about 0.01 $\mu\text{g}/\text{day}$ to about 100 $\mu\text{g}/\text{day}$ of said compound.

21. (Original) A method of treating a cancerous disease comprising administering to a patient with said disease an effective amount of a compound having the formula:



where Y₁ and Y₂, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group.

- 22. (Original) The method of claim 21 where the disease is leukemia.
- 23. (Original) The method of claim 21 where the disease is colon cancer.
- 24. (Original) The method of claim 21 where the disease is breast cancer.
- 25. (Original) The method of claim 21 where the disease is prostate cancer.
- 26. (Original) The method of claim 21 wherein the compound is administered orally.
- 27. (Original) The method of claim 21 wherein the compound is administered parenterally.
- 28. (Original) The method of claim 21 wherein the compound is administered transdermally.
- 29. (Original) The method of claim 21 wherein the compound is 2-methylene-19-nor-20(S)-25-methyl-1 α -hydroxycalciferol.

30. (Original) The method of claim 21 wherein the compound is administered in a dosage of from 0.01 μ g to 100 μ g per day.

31. (Original) (20S)-de-A,B-25-methylcholestan-8-one having the formula:

